27.07.2016 • NewsDede WillamsAirgasAir Liquide

Air Liquide Texas Plant Cited for Violations

The US Department of Labor’s Occupational Safety and Health Administration (OSHA) has cited Air Liquide’s US subsidiary for workplace health and safety violations at its Corpus Christi, Texas plant. The assessed penalties total $77,000. OSHA issued the citations for one “willful” and one “serious” violation. In the “willful” category, it said the French-headquartered group, world’s largest industrial gases producer since its $13.4 billion takeover of US competitor Airgas in May of this year, failed to perform air monitoring to assess employee exposure to carbon monoxide gas.

In the “serious” citation, the gases producer is said to have failed to protect workers from a potentially hazardous atmosphere created by inadequately maintained valves found leaking within the pressure swing adsorption skid. From the date the citations were issued, Jul. 20, Air Liquide has 15 business days to comply, request an informal conference with OSHA’s area director or contest the citations and penalties before the independent Occupational Safety and Health Review Commission.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.